Published today. Thirty six PubMed records were found by our Chief Scientific Director Dr. Korobko to be relevant and of interest, and were included into this quarterly overview. The review includes sections on epidemiology, comorbidities, quality of life, vitiligo triggers, new case reports, new clinical studies and trials, analysis of mechanisms of vitiligo pathogenesis, genetic studies, candidate biomarkers, mechanisms of treatments, methodological advancements and novel treatment modalities.
- Does halo nevi affect vitiligo development?
Halo nevi — nevi with an depigmented circle around it, usually on the trunk — are about 10x more common in vitiligo patients than in the general population, especially in childr...
- Is it possible to stop the progression of vitiligo?
It is true that vitiligo progression could be stopped in 4 out of 5 cases by the use of potent systemic corticosteroids - that is, oral medications. However, systemic corticost...
- I have vitiligo: will my children have vitiligo, too?
Children born to parents who both have the disorder are more likely to develop vitiligo. However, most children will not get vitiligo even if one parent has it. In children wit...
Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.Copyright (C) Bodolóczki Júlia
By taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.